Genmab AS (CHIX:GMABC) Tax Rate %: 28.38% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:GMABC Genmab AS CHIX:GMABC
92 GF Score
Price kr1,898.00
GF Value kr2,332.77
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Tax Rate %?

Genmab AS CHIX:GMABC 92 Tax Rate % is 28.38% as of Mar. 2026. GuruFocus rates CHIX:GMABC with a GF Score™ of 92/100 and a GF Value™ of kr2,332.77 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Genmab AS's Tax Expense for the three months ended in Mar. 2026 was kr136 Mil. Genmab AS's Pre-Tax Income for the three months ended in Mar. 2026 was kr478 Mil. Therefore, Genmab AS's Tax Rate % for the quarter that ended in Mar. 2026 was 28.38%.

Genmab AS Tax Rate % Related Terms

Genmab AS Tax Rate % Historical Data

* Premium members only.

The historical data trend for Genmab AS's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Tax Rate % Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.53 21.50 22.77 14.56 20.02

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.08 20.57 16.80 43.64 28.38
CHIX:GMABC
92GF Score
Genmab AS CHIX:GMABC
Tax Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Genmab AS's Tax Rate % for the fiscal year that ended in Dec. 2025 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2025 )/Pre-Tax Income (A: Dec. 2025 )
=1537.194/7679.594
=20.02 %

Genmab AS's Tax Rate % for the quarter that ended in Mar. 2026 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2026 )/Pre-Tax Income (Q: Mar. 2026 )
=135.771/478.432
=28.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of 28.38% mean?
Genmab AS (CHIX:GMABC) has a Tax Rate % of 28.38% as of Mar. 2026.
Is Genmab AS's Tax Rate % too high?
Genmab AS's current Tax Rate % is 28.38%. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Tax Rate % compare to VRTX and REGN?
Genmab AS's Tax Rate % of 28.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. Genmab AS's current Tax Rate % is 28.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,332.77, compared to a current price of kr1,898.00 — trading 18.6% below its estimated fair value. The current Tax Rate % is 28.38%. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Tax Rate % is 28.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (CHIX:GMABC) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of kr1,898.00 is trading 18.6% below its estimated GF Value™ of kr2,332.77. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for CHIX:GMABC:

  • Tax Rate %: 28.38%
  • GF Value™: kr2,332.77 vs. price of kr1,898.00 (18.6% below fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score

Get the complete analysis for CHIX:GMABC

Tax Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,898.00
Price
kr2,332.77
GF Value